Northern Trust Corp Akebia Therapeutics, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,635,099 shares of AKBA stock, worth $3.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,635,099
Previous 436,886 274.26%
Holding current value
$3.32 Million
Previous $445,000 384.94%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$0.94 - $1.55 $1.13 Million - $1.86 Million
1,198,213 Added 274.26%
1,635,099 $2.16 Million
Q2 2024

Aug 14, 2024
BUY
$0.86 - $1.63 $88,333 - $167,422
102,713 Added 30.74%
436,886 $445,000
Q1 2024

May 14, 2024
BUY
$1.27 - $2.24 $30,232 - $53,323
23,805 Added 7.67%
334,173 $611,000
Q4 2023

Feb 13, 2024
BUY
$0.8 - $1.28 $6,597 - $10,556
8,247 Added 2.73%
310,368 $384,000
Q3 2023

Nov 13, 2023
SELL
$0.87 - $1.84 $16,388 - $34,660
-18,837 Reduced 5.87%
302,121 $344,000
Q2 2023

Aug 11, 2023
SELL
$0.51 - $1.43 $26,265 - $73,645
-51,500 Reduced 13.83%
320,958 $295,000
Q1 2023

May 15, 2023
BUY
$0.56 - $1.15 $7,474 - $15,350
13,348 Added 3.72%
372,458 $208,000
Q4 2022

Feb 13, 2023
SELL
$0.25 - $0.58 $308 - $716
-1,235 Reduced 0.34%
359,110 $208,000
Q3 2022

Nov 14, 2022
SELL
$0.3 - $0.46 $54 - $83
-181 Reduced 0.05%
360,345 $114,000
Q2 2022

Aug 12, 2022
SELL
$0.32 - $0.67 $420,990 - $881,448
-1,315,595 Reduced 78.49%
360,526 $127,000
Q1 2022

May 13, 2022
SELL
$0.72 - $2.93 $50,351 - $204,903
-69,933 Reduced 4.01%
1,676,121 $1.2 Million
Q4 2021

Feb 08, 2022
SELL
$2.26 - $3.34 $59,024 - $87,230
-26,117 Reduced 1.47%
1,746,054 $3.95 Million
Q3 2021

Nov 15, 2021
BUY
$2.35 - $3.88 $191,203 - $315,688
81,363 Added 4.81%
1,772,171 $5.1 Million
Q2 2021

Aug 13, 2021
BUY
$2.83 - $4.2 $97,830 - $145,189
34,569 Added 2.09%
1,690,808 $6.41 Million
Q1 2021

May 12, 2021
SELL
$2.92 - $5.06 $266,806 - $462,342
-91,372 Reduced 5.23%
1,656,239 $5.61 Million
Q4 2020

Feb 11, 2021
SELL
$2.22 - $3.78 $97,859 - $166,626
-44,081 Reduced 2.46%
1,747,611 $4.89 Million
Q3 2020

Nov 16, 2020
BUY
$2.39 - $13.08 $42,965 - $235,139
17,977 Added 1.01%
1,791,692 $4.5 Million
Q2 2020

Aug 14, 2020
BUY
$6.67 - $13.58 $2.04 Million - $4.15 Million
305,838 Added 20.84%
1,773,715 $24.1 Million
Q1 2020

May 14, 2020
SELL
$4.1 - $10.24 $16,879 - $42,158
-4,117 Reduced 0.28%
1,467,877 $11.1 Million
Q4 2019

Feb 14, 2020
BUY
$3.16 - $6.73 $117,406 - $250,046
37,154 Added 2.59%
1,471,994 $9.3 Million
Q3 2019

Nov 13, 2019
BUY
$3.55 - $5.4 $1 Million - $1.52 Million
282,258 Added 24.49%
1,434,840 $5.62 Million
Q2 2019

Aug 13, 2019
BUY
$4.1 - $8.05 $127,247 - $249,839
31,036 Added 2.77%
1,152,582 $5.58 Million
Q1 2019

May 13, 2019
BUY
$5.41 - $8.73 $303,852 - $490,320
56,165 Added 5.27%
1,121,546 $9.19 Million
Q4 2018

Feb 12, 2019
BUY
$5.39 - $9.15 $2.32 Million - $3.94 Million
430,985 Added 67.94%
1,065,381 $5.89 Million
Q3 2018

Nov 14, 2018
BUY
$7.44 - $10.65 $157,794 - $225,875
21,209 Added 3.46%
634,396 $5.6 Million
Q2 2018

Sep 18, 2018
SELL
$9.15 - $11.34 $30,872 - $38,261
-3,374 Reduced 0.55%
613,187 $6.12 Million
Q2 2018

Aug 14, 2018
BUY
$9.15 - $11.34 $894,156 - $1.11 Million
97,722 Added 18.83%
616,561 $6.15 Million
Q1 2018

May 09, 2018
BUY
$9.53 - $15.68 $51,299 - $84,405
5,383 Added 1.05%
518,839 $4.94 Million
Q4 2017

Feb 14, 2018
SELL
$14.24 - $19.59 $24,193 - $33,283
-1,699 Reduced 0.33%
513,456 $7.64 Million
Q3 2017

Nov 13, 2017
BUY
$13.06 - $19.67 $6.73 Million - $10.1 Million
515,155
515,155 $10.1 Million

Others Institutions Holding AKBA

# of Institutions
121
Shares Held
54.8M
Call Options Held
291K
Put Options Held
179K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $373M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email